Stereotactic radiotherapy and oligometastases - Authors' reply

Affiliations

¹ King's Technology Evaluation Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EU, UK. Electronic address: anastasia.chalkidou@kcl.ac.uk.
² National Institute for Health and Care Excellence, Manchester, UK.
³ Clinical Oncology Department, Weston Park Hospital, Sheffield, UK.
⁴ Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
⁵ The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.

Comment

Anastasia Chalkidou et al. Lancet Oncol. 2021 Apr.

. 2021 Apr;22(4):e133.

doi: 10.1016/S1470-2045(21)00144-3.

¹ King's Technology Evaluation Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EU, UK. Electronic address: anastasia.chalkidou@kcl.ac.uk.
² National Institute for Health and Care Excellence, Manchester, UK.
³ Clinical Oncology Department, Weston Park Hospital, Sheffield, UK.
⁴ Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
⁵ The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.

No abstract available

Comment on

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N. Chalkidou A, et al. Lancet Oncol. 2021 Jan;22(1):98-106. doi: 10.1016/S1470-2045(20)30537-4. Lancet Oncol. 2021. PMID: 33387498
Stereotactic radiotherapy and oligometastases.
Macbeth F, Abratt R. Macbeth F, et al. Lancet Oncol. 2021 Apr;22(4):e132. doi: 10.1016/S1470-2045(21)00095-4. Lancet Oncol. 2021. PMID: 33794210 No abstract available.